CanSino Biologics Inc.

CASBFOTCHealthcare● Active

$3.97

+$0.97(+32.33%)

Market Cap$1.4B

P/E Ratio—

52W High$6.99

52W Low$3

Avg Volume49

Open$4.10

Beta1.16

Free Cash Flow Financials Revenue

CanSino Biologics Inc. (CASBF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CASBF · free cash flow · updated Jun 8, 2026

Core FCF metrics

CASBF · FCF · TTM · margin & CAGR

Free cash flow was −$152.8M for FY2025 (fiscal year ending 2025-12-31), up 75.6% year-over-year The FCF margin was -14.8%.

FY2025 Free Cash Flow−$152.8M▲ +75.6% YoY

Trailing 12M (TTM)−$137.4Mtrailing 4 quarters sum

FCF Margin-14.8%−$152.8M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CASBF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$32.5M(185M)−$152.8M▲ +75.6%-14.8%

FY2024−$168.8M(458M)−$626.4M▲ +59.0%-75.9%

FY2023−$908.2M(610M)−$1.53B▲ +48.5%-442.3%

FY2022−$1.89B(1.08B)−$2.96B▼ 465.1%-287.3%

FY2021$2.01B(1.20B)$811.4M▲ +209.6%18.9%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CASBF · P/FCF · FCF yield · FCF per share

CanSino Biologics Inc. (CASBF) reported negative free cash flow of −$0.15B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CASBF · cash flow statement · operating / investing / financing

For FY2025, CanSino Biologics Inc. generated $32.5M in operating cash flow and spent 185M in capital expenditures, yielding −$152.8M in free cash flow.

Operating Activities

+$32.5M

Cash from core business operations

2025-12-31

Investing Activities

+$355.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$703.1M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($32.5M) − |CapEx| (185M) = FCF (−$152.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CASBF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

CanSino Biologics Inc.YOU

CASBF

−$152.8M+75.6%-14.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

CanSino Biologics Inc. (CASBF) reported free cash flow of −$152.8M for FY2025 (fiscal year ending 2025-12-31), up 75.6% year-over-year. The FCF margin was -14.8%.

Based on available data, CanSino Biologics Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $811.4M in FY2021.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CASBF free cash flow · 8 questions

CanSino Biologics Inc. free cash flow was −$152.8M for FY2025, up 75.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$137.4M.

CASBF free cash flowCASBF FCFCASBF FCF 2025CASBF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · CanSino Biologics Inc. · CanSino Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026